Desouter AK, Keymeulen B, Demeester S, Van de Velde U, et al. Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetes. Diabetes Res Clin Pract 2023;205:110974.
PMID: 37884063